Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study).
Tamura N, Azuma T, Misaki K, Yamaguchi R, Hirano F, Sugiyama E, Kanai D, Murakawa Y, Oribe M, Kimata T, Aoki K, Sugiura T, Takasugi K, Takakubo Y, Tomita Y, Isozaki T, Nanki T, Katsuyama N, Kuroiwa T, Oshikawa H, Kaneko M, Fujinaga H, Saito K, Tanaka E, Inoue E, Yoshizawa Y, Matsumoto S, Yamanaka H, Harigai M. Tamura N, et al. Among authors: yamaguchi r. Mod Rheumatol. 2022 Aug 20;32(5):846-856. doi: 10.1093/mr/roab090. Mod Rheumatol. 2022. PMID: 34915575
Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E, Inoue E, Yamaguchi R, Shimizu Y, Kobayashi A, Sugimoto N, Hoshi D, Shidara K, Sato E, Seto Y, Nakajima A, Momohara S, Taniguchi A, Yamanaka H. Tanaka E, et al. Among authors: yamaguchi r. Mod Rheumatol. 2017 Mar;27(2):227-236. doi: 10.1080/14397595.2016.1205799. Epub 2016 Jul 29. Mod Rheumatol. 2017. PMID: 27472516
Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
Ochiai M, Tanaka E, Sato E, Inoue E, Abe M, Saka K, Sugano E, Sugitani N, Higuchi Y, Yamaguchi R, Sugimoto N, Ikari K, Nakajima A, Yamanaka H, Harigai M. Ochiai M, et al. Among authors: yamaguchi r. Mod Rheumatol. 2021 Jul;31(4):790-795. doi: 10.1080/14397595.2021.1883252. Epub 2021 Mar 1. Mod Rheumatol. 2021. PMID: 33538611
Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort.
Sugano E, Tanaka E, Inoue E, Sakai R, Abe M, Saka K, Sugitani N, Ochiai M, Yamaguchi R, Higuchi Y, Sugimoto N, Ikari K, Nakajima A, Yamanaka H, Harigai M. Sugano E, et al. Among authors: yamaguchi r. Mod Rheumatol. 2022 Jul 1;32(4):675-685. doi: 10.1093/mr/roab067. Mod Rheumatol. 2022. PMID: 34918127 Review.
Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort.
Tanaka E, Inoue E, Abe M, Saka K, Sugano E, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M. Tanaka E, et al. Among authors: yamaguchi r. Mod Rheumatol. 2022 Oct 15;32(6):1193-1195. doi: 10.1093/mr/roab120. Mod Rheumatol. 2022. PMID: 35445721 Free PMC article. No abstract available.
Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.
Tanaka E, Inoue E, Shoji A, Nilsson J, Papagiannopoulos C, Dhanda D, Yoshizawa Y, Abe M, Saka K, Sugano E, Sugitani N, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M. Tanaka E, et al. Among authors: yamaguchi r. PLoS One. 2022 Nov 16;17(11):e0277566. doi: 10.1371/journal.pone.0277566. eCollection 2022. PLoS One. 2022. PMID: 36383610 Free PMC article.
1,301 results